MEI PHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.065 USD | -1.13% |
|
-4.00% | -46.21% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the MEI Pharma Ph...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
Calendar
2024-05-08
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.1
USD
Average target price
23
USD
Spread / Average Target
+641.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.21% | 20.65M | |
| +1.75% | 42.59B | |
| +7.93% | 40.65B | |
| +48.60% | 40.57B | |
| -11.96% | 26.77B | |
| +8.34% | 24.81B | |
| -24.54% | 18.17B | |
| +27.90% | 12.05B | |
| -2.64% | 11.7B | |
| +7.39% | 11.1B |
- Stock Market
- Equities
- MEIP Stock
- News MEI Pharma, Inc.
- Transcript : MEI Pharma, Inc. - Special Call
